drugset / Trial / NCT03436797
A Study to Assess the Efficacy and Safety of AK002 in Subjects With Antihistamine-Resistant Chronic Urticaria
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 2a, open-label study to assess the effects of AK002
Timeline
- Start
- 2018-01-23
- Primary completion
- 2018-11-21
- Completion
- 2020-04-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | lirentelimab | Monoclonal antibody | 3 mg/kg | Intravenous |